其他
联拓生物引进！潜在“first-in-class”心血管药物拟纳入突破性治疗品种
▎药明康德内容团队报道
参考资料：
[2] MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy. Retrieved 2020-05-11, from https://myokardia.gcs-web.com/news-releases/news-release-details/myokardia-announces-primary-and-all-secondary-endpoints-met
[3] Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash, Retrieved October 5, 2020, from https://www.businesswire.com/news/home/20201005005381/en/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash
本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。
免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。